Pharmaceutical

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial OfficerKailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Industry executive with more than 25 years of finance and strategic leadership experienceBOSTON and SAN DIEGO, Jan. 08, 2025 (GLOBE…

1 hour ago
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed…

1 hour ago
Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technologyAraris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technology

Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technology

Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive…

1 hour ago
Collegium Provides 2025 Financial Guidance and Business UpdateCollegium Provides 2025 Financial Guidance and Business Update

Collegium Provides 2025 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue…

1 hour ago
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology PipelineWindtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder ValueWARRINGTON, Pa., Jan. 08, 2025…

1 hour ago
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated…

1 hour ago
Noema Pharma Appoints Michael Samar as Chief Financial OfficerNoema Pharma Appoints Michael Samar as Chief Financial Officer

Noema Pharma Appoints Michael Samar as Chief Financial Officer

Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & DevelopmentBASEL, Switzerland,…

1 hour ago
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced…

1 hour ago
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug CandidateCompass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract…

1 hour ago
ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa TrialViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial

ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial

VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal…

1 hour ago